$28.32
-0.75 (-2.58%)
Open$29.98
Previous Close$29.07
Day High$30.09
Day Low$27.98
52W High$40.65
52W Low$8.98
Volume—
Avg Volume1.20M
Market Cap1.68B
P/E Ratio—
EPS$-2.17
SectorBiotechnology
Analyst Ratings
Strong Buy
21 analysts
Price Target
-33.8% upside
Current
$28.32
$28.32
Target
$18.74
$18.74
$15.89
$18.74 avg
$31.24
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 572.13M | 572.72M | 559.98M |
| Net Income | -99,921,707 | -80,567,499 | -92,627,690 |
| Profit Margin | -17.5% | -14.1% | -16.5% |
| EBITDA | -119,066,634 | -104,548,216 | -110,415,827 |
| Free Cash Flow | -98,412,160 | -88,741,836 | -111,480,768 |
| Rev Growth | +16.0% | -4.7% | +5.4% |
| Debt/Equity | 0.49 | 0.55 | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |